Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income (2016 - 2025)

Zevra Therapeutics' Net Income history spans 11 years, with the latest figure at $12.2 million for Q4 2025.

  • For Q4 2025, Net Income rose 134.04% year-over-year to $12.2 million; the TTM value through Dec 2025 reached $83.2 million, up 178.88%, while the annual FY2025 figure was $83.2 million, 178.88% up from the prior year.
  • Net Income reached $12.2 million in Q4 2025 per ZVRA's latest filing, up from -$544000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $74.7 million in Q2 2025 to a low of -$35.7 million in Q4 2024.
  • Average Net Income over 5 years is -$5.5 million, with a median of -$4.9 million recorded in 2022.
  • Peak YoY movement for Net Income: surged 622.12% in 2021, then plummeted 674.39% in 2024.
  • A 5-year view of Net Income shows it stood at -$2.7 million in 2021, then fell by 9.95% to -$3.0 million in 2022, then crashed by 569.31% to -$19.9 million in 2023, then plummeted by 79.67% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Net Income are $12.2 million (Q4 2025), -$544000.0 (Q3 2025), and $74.7 million (Q2 2025).